Showing results (211-220 of 230) with videos related to
Sort By:
Pageof 23
Kardiologia Polska|March 23, 2023
Role of catheter-directed therapies in the treatment of acute pulmonary embolism. Expert opinion of the Polish PERT Initiative, Working Group on Pulmonary Circulation, Association of Cardiovascular Interventions, and Association of Intensive Cardiac Care of the Polish Cardiac SocietyGrzegorz Kopeć, Aleksander Araszkiewicz, Marcin Kurzyna, et al.Chest|November 11, 2024
Effects of β-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study: The Database of Pulmonary Hypertension in the Polish Population (BNP-PL)Marcin Waligóra, Marcin Kurzyna, Tatiana Mularek-Kubzdela, et al.Journal of the American College of Cardiology|March 25, 2017
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary EmbolismStavros V Konstantinides, Eric Vicaut, Thierry Danays, et al.Thrombosis and Haemostasis|September 24, 2021
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trialOlivier Sanchez, Anaïs Charles-Nelson, Walter Ageno, et al.The European Respiratory Journal|June 27, 2024
Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV studyDieuwke Luijten, Luca Valerio, Gudula J A M Boon, et al.Journal of Clinical Medicine|December 11, 2025
Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death PreventionŁukasz Ledziński, Grzegorz Grześk, Michał Ziołkowski, et al.ERJ Open Research|January 15, 2025
Cost-effectiveness of follow-up algorithms for chronic thromboembolic pulmonary hypertension in pulmonary embolism survivorsDieuwke Luijten, Wilbert B van den Hout, Gudula J A M Boon, et al.Journal of Clinical Medicine|March 14, 2026
Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Reply to Pagnoni et al. Toward Clinically Actionable Explainable AI in Pulmonary Arterial Hypertension: Endpoints, Calibration, and External Validation. Comment on "Ledziński et al. Personalized Medicine in Pulmonary Arterial Hypertension: Utilizing Artificial Intelligence for Death Prevention. J. Clin. Med. 2025, 14, 8325"Łukasz Ledziński, Grzegorz Grześk, Michał Ziołkowski, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|December 20, 2018
Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trialStefano Barco, Mariaconcetta Russo, Eric Vicaut, et al.Orphanet Journal of Rare Diseases|February 25, 2026
The prevalence and long-term response to calcium channel blockers in patients with pulmonary arterial hypertension and positive vasoreactivity test - results of multicenter national registry (BNP-PL)Michał Piłka, Szymon Darocha, Marcin Waligóra, et al.Pageof 23